Nitrosamine Impurities: Further Update of EMA's Question and Answer Document
The Q&A document developed by EMA and CMDh is updated at irregular intervals to reflect the latest knowledge. On 12 October 2022, the EMA published on its "What's new" website a new update of the Q&A document "Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamin impurities in human medicinal products" - now the 14th revision.
The document contains the following innovations:
Question 10: Which limits apply for nitrosamines in medicinal products?
The two nitrosamine compounds 4-(methylnitrosoamino)-1-(3-pyridinyl)-1-butanone (NKK) and N-nitrosoduloxetine were newly included in the table with corresponding limits (100 ng/day). The limit for nitrosoduloxetine was derived from structure-activity relationships. The value for NKK is based on the TD50 dataset of a database on carcinogenic potencies of numerous compounds (carcinogenic potency database; CPDB).
New question 21: What is the approach to control the presence of nitrosamines until a substance specific AI is established?
If new types of nitrosamine contaminants occur for which an acceptable intake (AI) has not yet been established due to a lack of toxicological data, a temporary limit, t-AI, of 178 ng/day (as the value for the sum of all nitrosamines present) can be applied. The validity of this t-AI value is 12 months, i.e. within this period no intervention (recall etc.) is required from the regulatory side for batches with a nitrosamine content up to 178 ng/day. If this period is exceeded, a special agreement with the authorities is required.
The t-AI value cannot be used automatically; a case-by-case assessment by the authority is required in each case.
Related GMP News
24.07.2024FDA Warning Letter to Chinese OTC Manufacturer for Lack of Analytical Test Data
10.07.2024Pharmeuropa: Two Revised Chapters on Dissolution Testing published for comments
03.07.2024FDA Warning Letter: GMP Requirements also apply to HPLC Analyses for Internal Use
12.06.2024NMPA Announcement on Application of ICH Q2(R2) and Q14 Principles
22.05.2024Q&As from the Live Online Training "Introduction to the AQCG's new AIQSV Guide" - Part 1
22.05.2024FDA Warning Letter to Contract Testing Laboratory in Uruguay due to Data Integrity Violations